The newly established Academy of Rare Patients in Greece aims to train its members to actively participate in the evaluation and approval processes of medical treatments at both European and international levels.
The Academy of Rare Patients Greece has officially launched with a mission to involve patients in the development and approval of medications. This academy represents one of the first initiatives in Europe, providing a structured program aimed at educating members about the processes involved in health technology assessment and regulatory approval for new drugs. It seeks to empower patients by training them to take part in discussions and decisions that impact their treatments and outcomes.
The curriculum includes training from professionals associated with the European Medicines Agency and specialized health technology assessment bodies. Distinguished educators, including regulatory officials from Greece and abroad, are part of the initiative to ensure a comprehensive understanding of the complexities involved in evaluating new medical technologies. The emphasis is on the critical role of patient involvement, enhancing the efficacy and relevance of the healthcare system to meet the needs of patients, particularly those with rare diseases.
By integrating patient voices into the approval process of drugs, the Academy aims to bridge the gap between medical professionals and patients, ensuring that treatment options are not only effective but also reflect the real-world experiences and expectations of those affected by rare diseases. This initiative may have significant implications for future drug approval processes, potentially leading to more personalized and patient-centric healthcare solutions.
